PLRZNasdaq
Polyrizon Ltd.
Healthcare·Healthcare·Ra'anana, Israel
Polyrizon Ltd. (PLRZ): 1 clinical trial. Updated within the last hour.
5.4/10
BioSniper Score
2-factor signal · derived from public data
Cash RunwayN/A
N/A
Financial Health10.0
0% dilution
Pipeline MaturityN/A
N/A
Pipeline BreadthN/A
N/A
Catalyst MomentumN/A
N/A
Insider Signal0.8
0 buys · 6 sells (180d)
A transparent, data-derived signal for Polyrizon Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$20.3M
Cash
$1.3M
Quarterly Burn
—
Runway
—
Revenue
—
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$117K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 10,149 | $117K |
| citigroup inc | 1 | $12 |
1 clinical trial·CEO: Mr. Tomer Izraeli
Frequently asked questions
What is Polyrizon Ltd.'s market capitalization?
Polyrizon Ltd.'s market capitalization is approximately $20.3M.
Who is the CEO of Polyrizon Ltd.?
Mr. Tomer Izraeli is the chief executive officer of Polyrizon Ltd. (PLRZ).
Get the full picture on Polyrizon Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.